Open AccessMinimal residual disease undetectable by next-generation sequencing predicts improved outcome in CLL after chemoimmunotherapy
Author(s) -
Philip A. Thompson,
Jaya Srivastava,
Christine B. Peterson,
Paolo Strati,
Jeffrey L. Jorgensen,
Tyler Hether,
Michael J. Keating,
Susan O’Brien,
Alessandra Ferrajoli,
Jan A. Burger,
Zeev Estrov,
Nitin Jain,
William G. Wierda
Publication year - 2019
Publication title -
blood
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.515
H-Index - 465
eISSN - 1528-0020
pISSN - 0006-4971
DOI - 10.1182/blood.2019001077
Subject(s) - chemoimmunotherapy , minimal residual disease , flow cytometry , residual , oncology , medicine , immunology , biology , rituximab , leukemia , lymphoma , computer science , algorithm
Thompson and colleagues report that detection of minimal residual disease using next-generation sequencing, which is 2 orders of magnitude more sensitive than flow cytometry, is a much better predictor of progression-free survival.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom